RxDoctor Payments Data

Fnu Arjun Saradna, MD

Critical Care Medicine · Greenwood Village, CONPI 1972047694

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Getinge USA Sales, LLC at 51.3% of the total. 2025 is the largest year on record at $1,414, more than ten times the $108 reported in 2023.

$1,948in general payments, 2019–2025

Across 28 payments — averaging $69.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Getinge USA Sales, LLC$999
  • Sanofi$177
  • AstraZeneca$168
  • Penumbra, Inc.$155
  • Abiomed$143
  • GSK$59
  • plus $245 from 10 others

What the payments were for

  • Travel & lodging$99951%
  • Food & beverage$94849%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,948 in reported general payments places this provider in the 70th percentile of 141 critical care medicine providers in Colorado.

See all critical care medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$90,685
Medicare patients
253
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,282
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$6,492
SymbicortBudesonide/Formoterol Fumarate15$3,117
Prednisone16$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$59$15,28219 claims
AstraZenecaSymbicort$168$3,11715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 141 critical care medicine providers in Colorado.

Other critical care medicine in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →